R&D at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's R&D?
- BioMarin Pharmaceuticals (BMRN) reported R&D of $178.8M in Q1 2026.
- How has BioMarin Pharmaceuticals's R&D changed year-over-year?
- BioMarin Pharmaceuticals's R&D increased by 12.6% year-over-year, from $158.73M to $178.8M.
- What is the long-term trend for BioMarin Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's R&D has grown at a 10.0% compound annual growth rate (CAGR), from $628.79M to $921.93M.
- What does R&D mean?
- Spending dedicated to creating new products and improving existing ones.
- How do you interpret R&D?
- Higher spending reflects a robust pipeline and commitment to innovation, though it reduces short-term profitability.
- How does R&D compare across companies?
- High R&D intensity is standard for biotech firms compared to mature pharmaceutical companies with lower pipeline risk.